Literature DB >> 23509348

The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma.

Katsunari Makino1, Masatoshi Jinnin, Ayaka Hirano, Keitaro Yamane, Mitsuhiko Eto, Takamitsu Kusano, Noritoshi Honda, Ikko Kajihara, Takamitsu Makino, Keisuke Sakai, Shinichi Masuguchi, Satoshi Fukushima, Hironobu Ihn.   

Abstract

Systemic and localized scleroderma (SSc and LSc) is characterized by excessive deposition of collagen and tissue fibrosis in the skin. Although they have fundamental common characteristics including autoimmunity, little is known about the exact mechanism that mediates the excessive collagen expression in these disorders. In the current study, we tried to evaluate the possibility that microRNAs (miRNAs) play some roles in the pathogenesis of fibrosis seen in these diseases. miRNA expression patterns were evaluated by miRNA array analysis, real-time PCR, and in situ hybridization. The function of miRNAs in dermal fibroblasts was assessed using miRNA inhibitors, precursors, or protectors. In the mouse model of bleomycin-induced dermal sclerosis, the overexpression of miRNAs was performed by i.p. miRNA injection. We demonstrated let-7a expression was downregulated in SSc and LSc skin both in vivo and in vitro, compared with normal or keloid skin. The inhibition or overexpression of let-7a in human or mouse skin fibroblasts affected the protein expression of type I collagen or luciferase activity of collagen 3'-untranslated region. Also, we found let-7a was detectable and quantitative in the serum and investigated serum let-7a levels in patients with SSc or LSc. let-7a concentration was significantly decreased in these patients, especially in LSc patients. Moreover, we revealed that the intermittent overexpression of let-7a in the skin by i.p. miRNA injection improved the skin fibrosis induced by bleomycin in mice. Investigation of more detailed mechanisms of miRNA-mediated regulation of collagen expression may lead to new therapeutic approaches against SSc and LSc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509348     DOI: 10.4049/jimmunol.1200822

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

Review 1.  The role of microRNAs in skin fibrosis.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-11       Impact factor: 3.017

Review 2.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 5.  From genetics to epigenetics: new insights into keloid scarring.

Authors:  Yongjing He; Zhenjun Deng; Mansour Alghamdi; Lechun Lu; Mark W Fear; Li He
Journal:  Cell Prolif       Date:  2017-01-05       Impact factor: 6.831

Review 6.  MicroRNA-21 in Skin Fibrosis: Potential for Diagnosis and Treatment.

Authors:  Yan Li; Juan Zhang; Yuying Lei; Lechun Lyu; Ruiling Zuo; Ting Chen
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

Review 7.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

Review 8.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 9.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

10.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.